Stryker Corporation
SYK Healthcare Medical Devices
Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.42%, EPS grew 43.1%, free cash flow grew 14.1% and total debt fell 9.88%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.
Follow SYK
Stryker Corporation (SYK) Revenue
Stryker Corporation's revenue for fiscal 2025 was $25.1B, up 11.2% from $22.6B in fiscal 2024. Over the twelve months to 30 June 2026 it was $25.8B. Over the past ten years it has ranged from $9.9B (fiscal 2015) to $25.1B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. Stryker Corporation ranks 3rd of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $25.1B | 11.16% |
| FY2024 | $22.6B | 10.23% |
| FY2023 | $20.5B | 11.11% |
| FY2022 | $18.4B | 7.84% |
| FY2021 | $17.1B | 19.21% |
| FY2020 | $14.4B | (3.58%) |
| FY2019 | $14.9B | 9.43% |
| FY2018 | $13.6B | 9.30% |
| FY2017 | $12.4B | 9.88% |
| FY2016 | $11.3B | 13.86% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $6.6B | 9.45% |
| Mar 2026 | $6.0B | (16.05%) |
| Dec 2025 | $7.2B | 18.39% |
| Sep 2025 | $6.1B | 0.58% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ABT Abbott Laboratories compare | $46.6B |
| MDT Medtronic PLC compare | $37.5B |
| SYK Stryker Corporation | $25.8B |
| GEHC GE HealthCare Technologies Inc. compare | $21.3B |
| BSX Boston Scientific Corporation compare | $21.0B |
| PHG Koninklijke Philips N.V. compare | $20.6B |
| EW Edwards Lifesciences Corporation compare | $6.5B |
| STE STERIS plc compare | $6.0B |
| DXCM DexCom, Inc. compare | $5.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on SYK
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement